BAVARIAN NORDIC AS

Their core work

Bavarian Nordic is a commercial biopharmaceutical company specializing in vaccine development and manufacturing, with a proprietary Modified Vaccinia Ankara platform (MVA-BN®) used as a viral vector backbone for multiple infectious disease vaccines. Their H2020 participation concentrated on two distinct but related capabilities: developing a rapid-access Ebola vaccine using a dual-vector regimen (Ad26.ZEBOV prime + MVA-BN®-Filo boost), and advancing vaccine lot-to-lot consistency testing methodologies as an alternative to traditional animal-based release assays. As an industry partner in academic-led consortia, they contribute commercial manufacturing scale-up expertise, GMP process knowledge, and regulatory pathway experience. Their work sits at the interface of product-specific vaccinology and broader manufacturing quality science.

What they specialise in

How they've shifted over time

In the first phase of their H2020 participation (2014-2017), Bavarian Nordic's work was disease-specific and crisis-driven — the EBOMAN project was a direct response to the West Africa Ebola outbreak, focused on rapidly establishing manufacturing capability for a dual-vector vaccine regimen using their MVA-BN®-Filo platform. By 2016 the focus shifted to platform-level manufacturing science: VAC2VAC (running through 2022) addressed vaccine lot consistency testing as a cross-product methodology applicable to many vaccines, not just Ebola. This arc — from emergency product manufacturing toward generalizable quality assurance standards — suggests deliberate repositioning toward regulatory and manufacturing methodology leadership.

Bavarian Nordic is moving from disease-specific vaccine production toward foundational manufacturing quality science, positioning themselves as industrial experts in vaccine consistency standards with cross-product regulatory relevance.

How they like to work

Bavarian Nordic participates exclusively as a consortium partner rather than coordinator, contributing specialized industrial manufacturing and quality capabilities to larger, typically academically-led consortia. With 26 unique partners across just 2 projects — averaging 13 partners per project — they operate in large multi-stakeholder collaborations consistent with IMI-style public-private health research programs. This pattern reflects the typical industry partner role: providing real-world manufacturing validation and regulatory expertise that academic partners cannot replicate, without taking on consortium management responsibilities.

Bavarian Nordic built a network of 26 unique partners across 7 countries from only 2 projects, indicating participation in large, densely connected health research consortia. Their network skews toward the European research area but reflects the globally relevant disease focus (Ebola response, pan-European vaccine standards) of their projects.

What sets them apart

As one of the few commercial vaccine manufacturers active in H2020 consortia, Bavarian Nordic offers something academic partners fundamentally cannot: a validated industrial manufacturing platform (MVA-BN®) with proven GMP scale-up and regulatory track record. Their dual expertise in both disease-specific vaccine production (Ebola) and cross-product quality methodology (lot consistency testing) makes them a bridge partner between early research and market/regulatory readiness. For any consortium needing a credible industry voice on vaccine manufacturability or release testing, they bring direct production-floor evidence rather than theoretical frameworks.

Highlights from their portfolio

• EBOMAN
  One of the first EU-funded projects to advance a dual-vector Ebola vaccine (Ad26.ZEBOV + MVA-BN®-Filo) through manufacturing development during the 2014 West Africa outbreak — a direct emergency response effort with real public health stakes.
• VAC2VAC
  A 6-year initiative (2016-2022) developing innovative consistency testing to replace animal-based lot-release assays, with potential regulatory implications across the entire vaccine industry.